NCT06907797 Tools for Reducing Inequity in Acute Leukemia (TRIAL): Beta Testing
| NCT ID | NCT06907797 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Dana-Farber Cancer Institute |
| Condition | Acute Leukemia |
| Study Type | INTERVENTIONAL |
| Enrollment | 75 participants |
| Start Date | 2025-04-01 |
| Primary Completion | 2027-05-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 75 participants in total. It began in 2025-04-01 with a primary completion date of 2027-05-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This study aims to test the Tools for Reducing Inequity in Acute Leukemia (TRIAL) web-based application that is designed to support participants with acute leukemia by providing information and resources about leukemia and clinical trial participation.
Eligibility Criteria
Inclusion Criteria: * Age 18 or older * English speaking * Ability to understand and willingness to sign written informed consent * Clinical suspicion of acute leukemia * Admitted to DFCI-affiliated inpatient unit Exclusion Criteria: * Cognitive impairment rendering the individual unable to participate in beta testing * This will be assessed by focused chart review and consultation with the patients' inpatient care team. * The following populations will be excluded: adults unable to consent, individuals who are not yet adults (infants, children, teenagers \<18 years old), prisoners. * Inability to participate in in-person application testing. * Patients who participated in alpha-testing through protocol 23-404 (Appendix A)
Contact & Investigator
Andrew Hantel, MD
PRINCIPAL INVESTIGATOR
Dana-Farber Cancer Institute
Frequently Asked Questions
Who can join the NCT06907797 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Acute Leukemia. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06907797 currently recruiting?
Yes, NCT06907797 is actively recruiting participants. Contact the research team at Andrew_hantel@dfci.harvard.edu for enrollment information.
Where is the NCT06907797 trial being conducted?
This trial is being conducted at Boston, United States.
Who is sponsoring the NCT06907797 clinical trial?
NCT06907797 is sponsored by Dana-Farber Cancer Institute. The principal investigator is Andrew Hantel, MD at Dana-Farber Cancer Institute. The trial plans to enroll 75 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.